A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Ovarian Cancer.

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure.

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures. According to GlobalData, Phase II drugs for Seizures have an 82% phase transition success rate ...

SPL-028 is under clinical development by Cybin and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase I drugs for Generalized Anxiety Disorder (GAD) have an 81 ...